ClinicalTrials.gg
RecruitingNCT07393542Updated Aug 14, 2026

A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma

A Phase 3 interventional study of SHR-A2102 and Adebrelimab and Gemcitabine and cisplatin / carboplatin in Locally Advanced or Metastatic Urothelial Carcinoma, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
453
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Carcinoma, Transitional Cell with a site in China — 51 open to participants now, 56 under way, 9 of them phase 3. Carcinoma, Transitional Cell · China.

Planned enrollment
10th of 69
453 · median 60
Started
2026
with 18 others
Phase 3
11 of 88
5 open now
Primary completion
2028-01
later than 42 of 55 live
Registered
70th of 88
by date

Among the 88 studies in Carcinoma, Transitional Cell with a site in China, this one is the 10th largest by planned enrollment of the 69 interventional ones that give a count, is one of 19 that started in 2026, is one of 11 in phase 3, reaches primary completion later than 42 of the 55 other live ones, and was the 70th registered.

Carcinoma, Transitional Cell

632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

51 of the 88 studies in Carcinoma, Transitional Cell with a site in China are open now. Recruiting first, the newest first:

45 more — sign in →

All 51 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Carcinoma, Transitional Cell with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy of SHR-A2102 with adebrelimab versus gemcitabine in combination with cisplatin/carboplatin in previously untreated locally advanced or metastatic urothelial carcinoma.

03

Conditions studied

  • Locally Advanced or Metastatic Urothelial Carcinoma
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be able to sign the form in writing.
  2. Female or male, 18 to 80 years of age (both inclusive).
  3. performance status of 0 or 1.
  4. Expected survival of≥ 3 months.
  5. confirmed diagnosis of urothelial carcinoma with radiographic or other confirmation of locally advanced unresectable or disease.
  6. No prior systemic therapy for locally advanced or metastatic disease.
  7. Able to provide archived or fresh tumor tissue for Nectin-4 and expression.
  8. According to v1.1, there must be at least one ;
  9. Tolerant to cisplatin or carboplatin.
  10. Adequate organ functions.
  11. Agree to use medically approved measures.

Exclusion criteria

Exclusion Criteria:

  1. Planned to receive any other anti-tumor therapy during the study.
  2. Received other products or treatments not yet marketed within 4 weeks.
  3. Have received systemic anti-tumor treatment within 4 weeks;have received prior anti-tumor Chinese patent medicine treatment within 2 weeks; palliative radiotherapy or local therapy within 2 weeks.
  4. Previously received therapy with an antibody-drug conjugate that meets any one of the following characteristics: targeting Nectin-4; containing irinotecan or its derivatives and acting as a topoisomerase I inhibitor.
  5. Prior treatment with .
  6. Major surgical procedure other than diagnostic or within 4 weeks, requiring elective surgery during the trial.
  7. Active disease requiring systemic treatment within 2 years.
  8. Have experienced adverse events caused by previous anti-tumor treatments that have not recovered to grade ≤1 as per v5.0.
  9. Uncontrolled central nervous system or carcinomatous meningitis.
  10. Subjects with clinical symptoms or serous cavity effusion requiring puncture drainage.
  11. Other within 5 years.
  12. History of pulmonary disease or any such disease suggested by chest imaging at screening.
  13. Serious infections requiring intravenous antibiotics, antivirals, or antifungals for control.
  14. Active virus (HBV) or virus (HCV) infection.
  15. History of immunodeficiency, or history of organ transplant.
  16. Have experienced arteriovenous thrombosis or cardiovascular and cerebrovascular accidents within 6 months.
  17. Subjects with clinically significant hemorrhage within 3 months.
  18. Glycosylated () ≥ 8%.
  19. Have serious cardiovascular and cerebrovascular diseases.
  20. Allergic reaction to any component of the study treatment.
  21. Subjects with active pulmonary tuberculosis.
  22. History of severe dry eye, active keratitis, or corneal ulcer, or other conditions.
  23. Female Subjects who are pregnant or planning to become pregnant during the study.
  24. Other conditions unsuitable into the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
453 participants (estimated)

Study arms

  • Experimental
    Treatment group 1

    SHR-A2102 and Adebrelimab

    Drug: SHR-A2102 and Adebrelimab

  • Active comparator
    Treatment group 3

    Gemcitabine and cisplatin / carboplatin

    Drug: Gemcitabine and cisplatin / carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free survival(PFS), assessed by BICR

    Time frame: up to 50 months

Secondary outcomes

  1. Overall Survival(OS)

    Time frame: up to 50 months

  2. Objective response rate(ORR), assessed by BICR

    Time frame: up to 50 months

  3. Disease control rate(DCR), assessed by BICR

    Time frame: up to 50 months

  4. Duration of response(DoR), assessed by BICR

    Time frame: up to 50 months

  5. PFS, assessed by investigator

    Time frame: up to 50 months

  6. ORR, assessed by investigator

    Time frame: up to 50 months

  7. DCR, assessed by investigator

    Time frame: up to 50 months

  8. DoR, assessed by investigator

    Time frame: up to 50 months

  9. Adverse event(AE)

    Time frame: up to 50 months

  10. serious adverse event(SAE)

    Time frame: up to 50 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jan 2028, 23 months after the start.

Of 28 phase 3 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 111. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2026
First posted
Feb 6, 2026
StartActual
Feb 12, 2026
Primary completionEst.
Jan 31, 2028
CompletionEst.
Oct 31, 2030
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07393542
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Feb 12, 2026
Primary completion
Jan 31, 2028 (estimated)
Completion
Oct 31, 2030 (estimated)
Last update
Aug 14, 2026

Study contacts

Chi Zhang
Contact
chi.zhang@hengrui.com
+8618456513908

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Notiretatug rezetecan · Adebrelimab

Start the discussion